Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Baricitinib
Therapeutic Area : Immunology
Study Phase : Phase II
Recipient : Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Baricitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Axial Spondyloarthritis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 02, 2023
Lead Product(s) : Baricitinib
Therapeutic Area : Immunology
Highest Development Status : Phase II
Recipient : Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Deal Size : Inapplicable
Deal Type : Inapplicable